Global Non-Melanoma Skin Cancer Market 2018-2022 | Increase in Incidence of Non-Melanoma Skin Cancer Symptoms to Boost Demand | Technavio

Technavio forecasts the global non-melanoma skin cancer market to grow at a CAGR of close to 6% by 2022. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global non-melanoma skin cancer market to grow at a CAGR of close to 6% during the forecast period, according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.

Surgery considered as a first-line curative approach for non-melanoma skin cancer treatment is one of the major trends being witnessed in the global non-melanoma skin cancer market 2018-2022. Despite the presence of an extensive range of non-surgical treatment modalities, surgery remains the first-line treatment for patients with non-melanoma skin cancer. This is because surgery results in the highest cure rate and provides superior outcomes in terms of complete lesion response, clearance of non-melanoma skin cancer and cumulative recurrence probabilities compared with cryotherapy or radiotherapy. Thus, surgery is considered as a first-line curative approach for non-melanoma skin cancer treatment.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

According to Technavio analysts, one of the key factors contributing to the growth of the global non-melanoma skin cancer market is the increase in the incidence of non-melanoma skin cancer symptoms:

Global non-melanoma skin cancer market: Increase in incidence of non-melanoma skin cancer symptoms

The incidence of non-melanoma skin cancer symptoms is increasing because of the unavailability of accurate data on non-melanoma skin cancer symptoms and mortality evolution. Non-melanoma skin cancer statistics are not available in most of the cancer registries. Thus, the true burden of non-melanoma skin cancer symptoms is not clear and is underestimated. Also, another challenge faced while determining the incidence rate of no-melanoma skin cancer is that the disease occurs predominantly among older age groups. As this population is not appropriately represented in most population registries, the incidence and mortality rates are naturally diminished.

According to a senior analyst at Technavio, “Non-melanoma skin cancer is among the most common types of cancers that affect the Americans. The white population in Europe, the US and Australia are highly affected by non-melanoma skin cancer (>1,000/100,000 person-years for BCC) as compared to the African population (<1/100,000 person-years for BCC). Europe registered a non-melanoma skin cancer incidence rate of 98 per 100,000 person-years and during 2006-2012, the prevalence of non-melanoma skin cancer population increased from 2.4 million to 3.3 million in the US alone.”

Global non-melanoma skin cancer market: Segmentation analysis

The global non-melanoma skin cancer market research report provides market segmentation by type of non-melanoma skin cancer (BCC and SCC) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

The Americas held the largest share of the market in 2017, accounting for close to 52% share. It was followed by EMEA and APAC respectively. The dominance of the Americas can be attributed to the increase in the incidence of non-melanoma skin cancer and non-melanoma skin cancer coverage and support.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio forecasts the global non-melanoma skin cancer market to grow at a CAGR of close to 6% by 2022.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com